CELLINK has completed a directed share issue of approximately SEK 100 million CELLINK AB (”CELLINK” or “the Company”) today announces that the Company has successfully completed a directed share issue of approximately SEK 100 million. The Board of Directors of CELLINK has, based on the issue authorization granted by the annual general meeting held 14 December 2017, and as communicated in the Company’s press release on 4 June 2018 (the “Directed Issue Announcement”), resolved on a directed share issue of 756,676 shares of series B at a subscription price of SEK 132.5 per share (the “Directed Issue”). The Directed Issue is now completed which means that the Company will receive gross proceeds of approximately SEK 100 million. The subscription price in the Directed Issue has been determined through an accelerated bookbuilding procedure.
The subscribers in the Directed Issue were a number of reputable Swedish and international institutional investors such as the Fourth Swedish National Pension Fund (AP4) and the current owners Carl Bennet AB, Claes Dinkelspiel and Handelsbanken Fonder.
The net proceeds of the Directed Issue are intended to be used for i) pursue acquisitions in line with the Company’s growth strategy ii) continue global expansion iii) organizational scale-up and iv) continue to develop the Company’s product portfolio.
The reasons for the deviation from the shareholders’ pre-emptive rights is to raise capital in a time efficient way at attractive terms in order to support a continued expansion and development of the Company’s operations. In addition, the deviation enables the Company to diversify the shareholder base with reputable Swedish and international investors, which is expected to improve the potential for greater liquidity in the listed shares of series B.
The issue entails a dilution of approximately 9.1 percent of the number of shares and approximately 6.5 percent of the number votes in the Company. The Directed Issue increases the number of outstanding shares by 756,676 from 7,566,763 to 8,323,439 and number of votes with 756,676 votes from 10,941,763 to 11,698,439. The share capital will increase by approximately SEK 75,668 from SEK 756,676 to SEK 832,344.
In order to facilitate the delivery of shares in the Directed Issue, Erik Gatenholm and Hector Martinez will jointly lend 756,676 shares of Class B to Carnegie.
will be returned after the Directed Issue has been registered at Swedish Companies Registration Office. In connected with the Directed Issue, Senior Executives and the Board of Directors have undertaken not to sell their respective shareholdings during a 180 day lock-up period.
Carnegie acted as Sole Bookrunner and Lead Manager in relation to the Directed Issue. Advokatfirman Vinge acted as legal advisor to CELLINK and Baker McKenzie acted as legal advisor to Carnegie.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO Telephone: +46 73 267 00 00 Telephone: +46 70 991 86 04 E-mail: firstname.lastname@example.org E-mail: email@example.com
This information is information that CELLINK AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 21.00 CET on 4 June 2018.
CELLINK has created one of the world’s first universal Bioinks, today used by many of the world’s most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK’s universal Bioink shows excellent results and can be used in both CELLINK’s proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. CELLINK is listed at Nasdaq First North under the ticker CLNK and Erik Penser Bank AB, tel: +46 8 463 80 00, is the Company’s Certified Adviser.
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in CELLINK in any jurisdiction, neither from CELLINK nor from someone else.
Any investment decision in connection with the Directed Issue must be made on the basis of all publicly available information relating to the Company and the Company’s shares. Such information has not been independently verified by Carnegie Investment Bank AB (publ). The information contained in this announcement is for background